FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?
German Firm Plans Both US And EU Launches In 2023
Executive Summary
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”
You may also be interested in...
Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).
Kabi: US Pegfilgrastim Crowd Is An Opportunity For Us, Not A Deterrent
In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.
Bio-Thera Claims A World First With Chinese Tocilizumab Approval
Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.